LABU Long ideaBuying LABU here, might be a little early. The price is above the 10 sma although many of the supporting averages are not aligned higher. Its more gambling than investing at this point.
PHARMA
Nasdaq Healthcare: Closing on January 16thToday's session generated a bearish divergence on CCI. I am still bullish, but always ready for a trend retracement on the 20 EMA Line.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Merck: Ichimoku Clouds on bullish setupIchimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Nasdaq Healthcare: Closing on January 15thIf you like this idea, don't forget to support it clicking the Like Button!
Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third candles (17:00 - 19:00)
The situation is also confirmed by RSI and CCI indicators.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Healthcare: Closing on January 14thGood session for the Nasdaq Healthcare Index, that closed the day with a 1.30% gain. Bullish sentiment is still driving trades. However next session could be characterized by a retracement around the basis of the Bollinger Bands indicator (orange crosses).
This is a daily analysis.
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
GWPH is a clear buyWow, great trend, much support. Hey, I've said it before I'll say it again, I'm no technical analysis guru. I think most of it is hooplah. Have you ever heard of the guys on Wall Street who threw darts at random stocks on a wall and those picks ended up performing better than most professional hedge fund managers? Yeahhh, exactly. I personally don't believe in most of these unicorn indicators. Goku flying on a Ichimoku cloud over here, fucking RSI up your ass over there. I don't look at any of it. (bUt YoU hAVe tHe RsI uP rIGhT nOw) shhhhhhh it's for giggles.
Now let me tell you what I do do (heh heh). I follow a rule I've established with myself before I go in and buy/sell a stock. I only commit to that action of exchanging the stock for cash or vice versa unless my conditions are met. Want to know what those conditions are? PSSHHHH. I'm not telling. Not that you care anyway. I'm not like, the best trader in the world. But I heavily believe part of trading is understanding the psychology of the market and beating the other guy - except for whale behavior but you can argue there's a psychological aspect to that as well (detecting that shit is hard tho) - so telling you my strategy is a joke and that's why I rarely believe in anyone who tells me there's.
Anyyyyywho. What I will reveal is my bullishness on GW Pharmaceuticals. I'll even reveal what prices I bought in at - an average cost of $103.13 and I will be buying more good sir. I took a look at this companies balance sheet compared to last year and I swear I got half a chub. For one, GWPH's product Epidolex has competitor advantage being the only FDA approved cannabidiol product to treat two forms of epilepsy in children. Over 18,000 children suffer from LGS and Dravet Syndrome in America (the forms of epilepsy the prescription treats). As of now 7,600 patients have received Epidolex for treatment resulting in $31 million in sales for this product. Future sales can potentially double just for America alone. The company is gearing up in the EU market as well. Not to mention they are testing the same prescription in treating a disease that affects 1-2 million people worldwide. This baby is going to the moon given FDA approval for the treatment. But of course that's an "if". Considering the hard facts I like that the companies' assets are outpacing its liabilities and looking at last years' balance sheet compared to this years' this stock was either grossly over valued last year and slightly under valued this year or damn near bubble euphoria territory last year and fairly priced this year. There could be a third scenario that this stock price is still overvalued but man does this companies growth story look attractive. I'm buying!!
P.S - I am a random dude who doesn't know shit about shit. I'm just reading books, reading balance sheets, watching YouTube videos trying to figure out how to value businesses. I got involved in the stock market 3 years ago and I'm just straight up passionate about it dawg. Think it was my real calling truth be told. I'm documenting for future purposes. Follow my trades if you want, just don't cry if you randomly read this and got convinced to buy something because of a stranger. I learned the hard way to never do that again. I only read other peoples recommendations of stocks to get an understanding of how other peeps are valuating companies. I don't even read that trade junk anymore, I've already got my set of rules. And I also only execute very few trades because as we know most traders do not beat the market. If you think you can I encourage you to try to get into an Ivy league cuz you're chances are roughly the same. Good luck out there folks. Holla atcha boy
$TTNP - Set up for a Growth Stock in 2020 5 X + CandidateI will update this article I just wanted to get the idea down because this is capable of 2-4 x in short amount of time..
So rough notes but wanted to have it documented real time
Analyst have maintained a .75 and 1 target here which is at the very least 3-4 x from current prices.
$TTNP - Going to be a 5-10 X candidate 2020
For a swing trade .
2020 will be the first year company will become a growth stock
Major analyst have a 1 target on this as unlikely FINRA will allow for another RS so soon.
So they have 1 option get the stock over 1... Remember even company has the option doesn't mean FINRA will approve.
Analyst have also maintained a .75 and 1 target here which is at the very least 3-4 x from current prices.
The last Bio tech i posted on went 10x in a short amount of time and $TTNP has tremendous upside going forward as much of bad news is behind them. They laid down the infastructure for growth in 2019 so 2020 should be a growth year.
Sadly, the Opioid crisis isnt going away. $TTNP is positioned to help the fight against the epidemic and should also profit with that endeavor.
$TTNP has 5-10x + potential chart has lots of gaps up
Do your DD , recent board appointment and all the ground work laid in 2019 for it to become a growth stock in 2020.
My thoughts ..
TTNP is at .20 now
Alexion: Today's opening is confirming the bullish assumptionGood spot for Alexion Pharmaceuticals. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud).
I was waiting for today's opening to confirm a bullish position.
Furthermore, Alexion trades below its normal Price/Ebitda ratio of 41.13 (currently trading at 11.89).
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
Biogen: Further GrowthAfter the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase.
I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an exciting phase, testing the high line of the cloud with a bullish configuration, as also confirmed by the Stochastic.
The upward trend is also confirmed by fundamental analysis. Biogen counts on a strong collaboration with Roche in oncology, and on growing revenues thanks to Ocrevus (Multiple Sclerosis), as well as to a significant pipeline.
Furthermore, the complexity of Biogen's drugs makes the production of Biosimilars difficult.
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
SNOA: $4.35 | Sold Out Shares & Under Valuedwith new products addressing aesthetic industry should recover when volume
starts to kick in
PFE Bump and Run!PFE is a large pharmaceutical company that specialises in biopharmaceuticals. As you can see there has been a large bump and run from the upward trend in the past, which led to a death-cross. Gaussian channel shows a clear upward trend. Green fractal indicates a follow up bump and run.
$MNK Go timeAscending Wedge Reversal.
Volume is there and ready to go.
Generic opioid manufacturers have been beaten down recently over fear of a copious monetary fine, but MNK has an established diverse profile.
Do NOT miss this stock when it runs.
Break above $4.15 and were off
Long Term Target: $12.90
Will Glaxosmithkline break out?Pressure is building and a breakout could be imminent.
It's taken 6 years from May 2013 where the high was 1816
Needs substantive news to make the push over the 1750s
VSTM - Bear Trend ReversalBear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly.
These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR).
I've previously played these directly on the instrument, but this time I'm playing this with 10 buys of $2 March 20, 2020 calls. Hoping to see a continued surge of implied volatility for these options as I don't plan on holding them through expiry. That being said, I've yet to really win on any of my options trades...but IV is on the up and up since my purchase so we'll just have to wait'n'see.
Biomarin Pharmaceutical - downtrend over?Waiting for at least 3 closes above the 200sma to confirm new uptrend.
Johnson & Johnson - Healthcare outperformingJNJ has breached its 200sma resistance, to enter "channel 1".
I would wait 2-3 closes inside the channel above the 200sma to enter a position.
Profit-exit ---> $144.2
Stop-loss ---> $133.19
Approximate RRR ---> 3:1
DRG - Pharmaceuticals Finding Relative StrengthDRG broke out of a consolidation period during yesterday's trading & continued its bullish momentum today. The industry is also beginning to find relative strength against the SPX. This could be an industry worth looking around in to find some stocks to provide alpha if it continues to strengthen.
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide.
Market Cap: £4.79Billion
The long-term trend on Hikma remains bullish. The corrective move lower in recent weeks has found some support at the 38.2% Fibonacci level. The posting of a bullish engulfing candle while simultaneously breaking from a wedge pattern is bullish for short term sentiment. Further upside is expected from here, targeting the previous highs at 2345p from 15th March 2017.
Stop: 1920p
Target 1: 2210p
Target 2: 2345p
Target 3: 2400p
Interested in UK Stocks?
Join our free Telegram channel for up to date analysis on the best main market opportunities in the UK right now - t.me
Farmacéuticas al Alzathe pharmaceuticals are performing well so the market makers are currently buying on this sector, my principal list on this sector are AMGEN, PFIZER and BRISTOL MYERS, i'm waiting to break levels to buy
Will Kaya make Porinju Veliyath Right? - 70% Fall in 15 Months 1200 to 360... 70% Fall in 15 Months of Kaya Health Care. Any Guesses on what this will do for Porinju veliyath & Equity "Intelligence" ?
#TORNTPHARM Cup and Handle Breakout @anish_sharmaaa#TORNTPHARM Cup and Handle Breakout @anish_sharmaaa
View negated below 1595...
